Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Experimental Neurology

• Publication date

  2012-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.expneurol.2011.11.036PMID 22173317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Probucol therapy improves long-term (>10-year) survival after complete revascularization: a propensity analysis.

  2012cited by this paper
• The Pathogenesis of Alzheimer's Disease: A Reevaluation of the “Amyloid Cascade Hypothesis”

  2011cited by this paper
• Simvastatin and other HMG-CoA reductase inhibitors on brain cholesterol levels in Alzheimer's disease.

  2011cited by this paper
• Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease.

  2011cited by this paper
• Effect of oxidative stress induced by paradoxical sleep deprivation on the activities of Na+, K+-ATPase and acetylcholinesterase in the cortex and hippocampus of rat.

  2011cited by this paper
• Linking lipids to Alzheimer's disease: cholesterol and beyond

  2011cited by this paper
• The cholinergic system in aging and neuronal degeneration.

  2011cited by this paper
• Apolipoprotein E in Alzheimer's disease and other neurological disorders.

  2011cited by this paper
• Folic Acid Plus α-Tocopherol Mitigates Amyloid-β-Induced Neurotoxicity through Modulation of Mitochondrial Complexes Activity

  2011cited by this paper
• The cerebrovascular role of the cholinergic neural system in Alzheimer's disease.

  2011cited by this paper
• Pharmacokinetics and tolerability of probucol after multiple oral administrations in healthy volunteers.

  2011cited by this paper
• Preventive and therapeutic types of environmental enrichment counteract beta amyloid pathology by different molecular mechanisms.

  2011cited by this paper
• Amyloid cascade hypothesis

  2011cited by this paper
• Kynurenines, neurodegeneration and Alzheimer’s disease

  2010cited by this paper
• APOE and cholesterol homeostasis in Alzheimer's disease.

  2010cited by this paper
• Low‐density lipoprotein receptor‐related protein‐1: a serial clearance homeostatic mechanism controlling Alzheimer’s amyloid β‐peptide elimination from the brain

  2010cited by this paper
• Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage.

  2010cited by this paper
• Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: implications for dementia risk.

  2010cited by this paper
• Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases

  2010cited by this paper
• Altered Levels of Acetylcholinesterase in Alzheimer Plasma

  2010cited by this paper
• Object recognition memory and the rodent hippocampus.

  2010cited by this paper
• Probucol increases glutathione peroxidase-1 activity and displays long-lasting protection against methylmercury toxicity in cerebellar granule cells.

  2009cited by this paper
• The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal

  2009cited by this paper
• Mild cholesterol depletion reduces amyloid‐β production by impairing APP trafficking to the cell surface

  2009cited by this paper
• Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease.

  2009cited by this paper
• Where are we with probucol: a new life for an old drug?

  2009cited by this paper
• Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

  2008cited by this paper
• Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study

  2008cited by this paper
• Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan.

  2008cited by this paper
• Differential susceptibility following beta-amyloid peptide-(1-40) administration in C57BL/6 and Swiss albino mice: Evidence for a dissociation between cognitive deficits and the glutathione system response.

  2007cited by this paper
• Connecting TNF-α Signaling Pathways to iNOS Expression in a Mouse Model of Alzheimer's Disease: Relevance for the Behavioral and Synaptic Deficits Induced by Amyloid β Protein

  2007cited by this paper
• Targeting acetylcholinesterase to treat neurodegeneration

  2007cited by this paper
• Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein.

  2007cited by this paper
• Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats.

  2007cited by this paper
• Probucol promotes endogenous antioxidant reserve and confers protection against reperfusion injury.

  2007cited by this paper
• Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects.

  2007cited by this paper
• Characteristics of object location memory in mice: Behavioral and pharmacological studies.

  2007cited by this paper
• Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide

  2007cited by this paper
• Differential susceptibility following β-amyloid peptide-(1–40) administration in C57BL/6 and Swiss albino mice: Evidence for a dissociation between cognitive deficits and the glutathione system response

  2007cited by this paper
• Probucol inhibits in-stent thrombosis and neointimal hyperplasia by promoting re-endothelialization.

  2006cited by this paper
• Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment.

  2006cited by this paper
• A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on β-amyloid and α-synuclein

  2006cited by this paper
• A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on beta-amyloid and alpha-synuclein.

  2006cited by this paper
• Effects of atorvastatin on blood-brain barrier permeability during L-NAME hypertension followed by angiotensin-II in rats.

  2005cited by this paper
• Deciphering the molecular basis of memory failure in Alzheimer's disease.

  2004cited by this paper
• Colocalization of cholinesterases with β amyloid protein in aged and Alzheimer's brains

  2004cited by this paper
• Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use.

  2004cited by this paper
• Senile plaques: staining for acetylcholinesterase and A4 protein: a comparative study in the hippocampus and entorhinal cortex

  2004cited by this paper
• Pathways towards and away from Alzheimer's disease

  2004cited by this paper
• Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease.

  2003cited by this paper
• The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease.

  2003cited by this paper
• Glutathione Pathways in the Brain

  2003cited by this paper
• In Vivo Imaging of Reactive Oxygen Species Specifically Associated with Thioflavine S-Positive Amyloid Plaques by Multiphoton Microscopy

  2003cited by this paper
• Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.

  2002cited by this paper
• Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease.

  2002cited by this paper
• Reactivity to object and spatial novelty is normal in older Ts65Dn mice that model Down syndrome and Alzheimer's disease.

  2002cited by this paper
• Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress

  2002cited by this paper
• Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

  2002cited by this paper
• The cardiology patient page. Statins: powerful drugs for lowering cholesterol: advice for patients.

  2002cited by this paper
• Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease.

  2002cited by this paper
• Cholesterol Accumulates in Senile Plaques of Alzheimer Disease Patients and in Transgenic APPsw Mice

  2001cited by this paper
• Statins and the risk of dementia.

  2000cited by this paper
• Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease

  1998cited by this paper
• The Amyloid β‐Protein of Alzheimer's Disease Increases Acetylcholinesterase Expression by Increasing Intracellular Calcium in Embryonal Carcinoma P19 Cells

  1997cited by this paper
• Frequency of stages of Alzheimer-related lesions in different age categories.

  1997cited by this paper
• The differences shown by C57BL/6 and DBA/2 inbred mice in detecting spatial novelty are subserved by a different hippocampal and parietal cortex interplay.

  1996cited by this paper
• Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease.

  1996cited by this paper
• β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease

  1996cited by this paper
• The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.

  1996cited by this paper
• Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect.

  1995cited by this paper
• NMDA-dependent superoxide production and neurotoxicity

  1993cited by this paper
• Alzheimer's disease: the amyloid cascade hypothesis.

  1992cited by this paper
• Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.

  1992cited by this paper
• Probucol, a superoxide free radical scavenger in vitro.

  1991cited by this paper
• Influence of probucol on early experimental atherogenesis in hypercholesterolemic rats.

  1989cited by this paper
• Increased levels of messenger ribonucleic acid for apolipoprotein E in the spleen of probucol-treated rabbits.

  1988cited by this paper
• Prevention of atherosclerotic progression in Watanabe rabbits by probucol.

  1988cited by this paper
• Glutathione reductase.

  1985cited by this paper
• [59] Glutathione reductase

  1985cited by this paper
• Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: selective loss of the intermediate (10S) form.

  1983cited by this paper
• [44] Glutathione peroxidase

  1981cited by this paper
• Glutathione peroxidase.

  1981cited by this paper
• Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction.

  1979cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• A new and rapid colorimetric determination of acetylcholinesterase activity.

  1961cited by this paper
• Tissue sulfhydryl groups.

  1959cited by this paper

• Probucol attenuates bone loss in APP/PS1 mice and ameliorates Aβ42-induced osteoblast dysfunction by regulating AKT/FOXO3a signaling pathway.

  2026cites this paper
• Role of apolipoprotein E4 in alzheimer’s disease pathogenesis and emerging therapeutic strategies

  2025cites this paper
• APOE-Targeted Therapeutics for Alzheimer's Disease

  2025cites this paper
• Revolutionizing drug delivery strategies with probucol to Combat oxidative stress in retinal Degeneration: A comprehensive review.

  2025cites this paper
• New Approach for Targeting Small-Molecule Candidates for Intrinsically Disordered Proteins

  2025cites this paper
• Probucol-bile acid based nanoparticles protect auditory cells from oxidative stress: an in vitro study.

  2024cites this paper
• Application of CRISPR/Cas9 System in the Treatment of Alzheimer’s Disease and Neurodegenerative Diseases

  2024cites this paper
• The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases

  2024cites this paper
• Effects of Probucol on plasma amyloid-β transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial

  2024cites this paper
• Neuroprotective Effects of Probucol against Rotenone-Induced Toxicity via Suppression of Reactive Oxygen Species Production in SH-SY5Y Cells.

  2024cites this paper
• Probucol mitigates high-fat diet-induced cognitive and social impairments by regulating brain redox and insulin resistance

  2024cites this paper
• Roles of ApoE4 on the Pathogenesis in Alzheimer’s Disease and the Potential Therapeutic Approaches

  2023cites this paper
• Alzheimer’s Disease: a Search for the Best Experimental Models to Decode Cellular and Molecular Mechanisms of Its Development

  2023cites this paper
• Probucol neuroprotection against manganese-induced damage in adult Wistar rat brain slices

  2023cites this paper
• Probucol mitigates high-fat diet-induced cognitive and social impairments through disruption of redox-inflammation association

  2023cites this paper
• Mesenchymal stem cell‐derived rapid drug screening system for Alzheimer's disease for the identification of novel drugs

  2023influential citation
• Novel Probucol Analogue, 4,4'-Diselanediylbis (2,6-Di-tert-Butylphenol), Prevents Oxidative Glutamate Neurotoxicity In Vitro and Confers Neuroprotection in a Rodent Model of Ischemic Stroke.

  2023cites this paper
• APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer’s Disease pathology

  2023cites this paper
• Research and progress of probucol in nonalcoholic fatty liver disease.

  2023cites this paper
• Selenium-derivative compounds: a review of new perspectives in the treatment of Alzheimer's disease.

  2022cites this paper
• A Novel Diselenide-Probucol-Analogue Protects Against Methylmercury-Induced Toxicity in HT22 Cells by Upregulating Peroxide Detoxification Systems: a Comparison with Diphenyl Diselenide

  2022cites this paper
• Redefining oxidative stress in Alzheimer's disease: Targeting platelet reactive oxygen species for novel therapeutic options.

  2022cites this paper
• Protective Effects of Probucol on Different Brain Cells Exposed to Manganese

  2022cites this paper
• Cilostazol and Probucol for Cognitive Decline after Stroke: A Cognitive Outcome Substudy of the PICASSO Trial

  2021cites this paper
• APOE and Alzheimer’s Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches.

  2021cites this paper
• Prevention of ferroptosis in acute scenarios: an in vitro study with classic and novel anti-ferroptotic compounds

  2021cites this paper
• Effects and mechanisms of probucol on aging-related hippocampus-dependent cognitive impairment.

  2021cites this paper
• Blood pressure variability is related to faster cognitive decline in ischemic stroke patients: PICASSO subanalysis

  2021cites this paper
• Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview

  2021cites this paper
• Probucol Protects Neuronal Cells Against Peroxide-Induced Damage and Directly Activates Glutathione Peroxidase-1

  2020cites this paper
• Alzheimer's disease pathology in ApoE transgenic mouse models: The Who, What, When, Where, Why, and How.

  2020cites this paper
• New Probucol Analogues Inhibit Ferroptosis, Improve Mitochondrial Parameters, and Induce Glutathione Peroxidase in HT22 Cells

  2020cites this paper
• Neuroprotective role of alendronate against APP processing and neuroinflammation in mice fed a high fat diet.

  2020cites this paper
• Probucol, a “non-statin” cholesterol-lowering drug, ameliorates D-galactose induced cognitive deficits by alleviating oxidative stress via Keap1/Nrf2 signaling pathway in mice

  2019cites this paper
• Effects of Solvent Stabilization on Pharmaceutical Crystallization: Investigating Conformational Polymorphism of Probucol Using Combined Solid-State Density Functional Theory, Molecular Dynamics, and Terahertz Spectroscopy.

  2019cites this paper
• Effect of probucol on autophagy and apoptosis in the penile tissue of streptozotocin-induced diabetic rats

  2019cites this paper
• Design, Synthesis, and In Vitro Evaluation of a Novel Probucol Derivative: Protective Activity in Neuronal Cells Through GPx Upregulation

  2018cites this paper
• Effect of probucol on hemodynamics, rheology and blood lipid of diabetic retinopathy

  2018cites this paper
• Effects of perinatal exposure to n-3 polyunsaturated fatty acids and methylmercury on cerebellar and behavioral parameters in mice.

  2018cites this paper
• Probucol prevents blood–brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet

  2018cites this paper
• Antidepressant Effects of Probucol on Early-Symptomatic YAC128 Transgenic Mice for Huntington's Disease

  2018cites this paper
• Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration.

  2018cites this paper
• Probucol improves erectile function via Activation of Nrf2 and coordinates the HO-1 / DDAH / PPAR-γ/ eNOS pathways in streptozotocin-induced diabetic rats.

  2018cites this paper
• The Alzheimer’s disease transcriptome mimics the neuroprotective signature of IGF-1 receptor-deficient neurons

  2017cites this paper
• Involvement of superoxide in malaoxon-induced toxicity in primary cultures of cortical neurons

  2017cites this paper
• Thymoquinone-rich fraction nanoemulsion (TQRFNE) decreases Aβ40 and Aβ42 levels by modulating APP processing, up-regulating IDE and LRP1, and down-regulating BACE1 and RAGE in response to high fat/cholesterol diet-induced rats.

  2017cites this paper
• Activation of the Nrf2/ARE signaling pathway by probucol contributes to inhibiting inflammation and neuronal apoptosis after spinal cord injury

  2017influential citation
• The contribution of transgenic and nontransgenic animal models in Alzheimer’s disease drug research and development

  2017cites this paper
• Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective

  2016cites this paper
• Probucol and Succinobucol display similar lipid-lowering and antioxidant effects : a subacute / subchronic study in mice

  2016cites this paper
• Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage.

  2016cites this paper
• Probucol inhibits neural cell apoptosis via inhibition of mTOR signaling pathway after spinal cord injury.

  2016cites this paper
• Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity

  2016cites this paper
• Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson’s Disease

  2016cites this paper
• Decreased forelimb ability in mice intracerebroventricularly injected with low dose 6-hydroxidopamine: A model on the dissociation of bradykinesia from hypokinesia.

  2016cites this paper
• Long-term and low-dose malathion exposure causes cognitive impairment in adult mice: evidence of hippocampal mitochondrial dysfunction, astrogliosis and apoptotic events

  2015cites this paper
• Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice.

  2015influential citation
• B₂ receptor blockage prevents Aβ-induced cognitive impairment by neuroinflammation inhibition.

  2015cites this paper
• Is There a Link between Saturated Fat Intake and Alzheimer’s disease?

  2015cites this paper
• Effect of Capparis spinosa L. on cognitive impairment induced by D-galactose in mice via inhibition of oxidative stress.

  2015cites this paper
• Cholesterol Levels and Cognitive Impairments

  2015cites this paper
• Hypercholesterolemia induces short-term spatial memory impairments in mice: up-regulation of acetylcholinesterase activity as an early and causal event?

  2014cites this paper
• New insights on Alzheimer's disease

  2014cites this paper
• Implication du récepteur LSR (lipolysis stimulated lipoprotein receptor) dans le contrôle de l’homéostasie du cholestérol cérébral et les capacités cognitives au cours du vieillissement

  2014cites this paper
• Methionine Stimulates Motor Impairment And Cerebellar Mercury Deposition in Methylmercury-Exposed Mice

  2014cites this paper
• Increased Susceptibility to Amyloid-β-Induced Neurotoxicity in Mice Lacking the Low-Density Lipoprotein Receptor

  2014cites this paper
• Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.

  2014cites this paper
• Long-term probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction

  2014cites this paper
• Statins are Protective Against Beta-amyloid Pathology in Alzheimer's Disease ?

  2013cites this paper
• Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia.

  2013cites this paper
• Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-β (Aβ(1-40)) administration in mice.

  2013cites this paper
• Probucol Affords Neuroprotection in a 6-OHDA Mouse Model of Parkinson’s Disease

  2013cites this paper
• Discovering new treatments for Alzheimer's disease by repurposing approved medications.

  2013cites this paper
• Probucol prevents blood–brain barrier dysfunction in wild‐type mice induced by saturated fat or cholesterol feeding

  2013cites this paper
• Succinobucol versus probucol: higher efficiency of succinobucol in mitigating 3-NP-induced brain mitochondrial dysfunction and oxidative stress in vitro.

  2013cites this paper
• The effects of perindopril on cognitive impairment induced by d-galactose and aluminum trichloride via inhibition of acetylcholinesterase activity and oxidative stress.

  2013cites this paper
• Probucol Increases Striatal Glutathione Peroxidase Activity and Protects against 3-Nitropropionic Acid-Induced Pro-Oxidative Damage in Rats

  2013cites this paper
• Neuroprotective Effect of Physical Exercise in a Mouse Model of Alzheimer’s Disease Induced by β-Amyloid1–40 Peptide

  2013influential citation
• Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer’s disease (AD)

  2012cites this paper
• Does methylmercury-induced hypercholesterolemia play a causal role in its neurotoxicity and cardiovascular disease?

  2012cites this paper
• Age-Related Cognitive Decline in Hypercholesterolemic LDL Receptor Knockout Mice (LDLr−/−): Evidence of Antioxidant Imbalance and Increased Acetylcholinesterase Activity in the Prefrontal Cortex

  2012cites this paper
• Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.

  2012cites this paper
• Overexpression of cellular prion protein (PrP(C)) prevents cognitive dysfunction and apoptotic neuronal cell death induced by amyloid-β (Aβ₁₋₄₀) administration in mice.

  2012cites this paper
• Papel do receptor B2 para as cininas na neuroinflamação induzida pelo peptídeo beta-amilóide

  2012cites this paper
• EXPLORATION OF THERAPEUTIC POTENTIAL OF PROBUCOL IN SCOPOLAMINE INDUCED MEMORY IMPAIRMENT IN SWISS ALBINO MICE

  year unknowncites this paper